Our data demonstrate that although IL-6 may be essential for the activation of STAT3 in our cervical cancer cell culture system, the heterogeneity of IL-6 expression observed in clinical samples of cervical disease and cervical cancers warrants further investigation to allow the proper stratification of potential therapeutics targeting this pathway. The gene discussed is STAT3; the disease is cervical cancer.